Cargando…

Paradoxically Greater Persistence of HIV RNA-Positive Cells in Lymphoid Tissue When ART Is Initiated in the Earliest Stage of Infection

Starting antiretroviral therapy (ART) in Fiebig 1 acute HIV infection limits the size of viral reservoirs in lymphoid tissues, but does not impact time to virus rebound during a treatment interruption. To better understand why the reduced reservoir size did not increase the time to rebound we measur...

Descripción completa

Detalles Bibliográficos
Autores principales: Kroon, Eugène, Chottanapund, Suthat, Buranapraditkun, Supranee, Sacdalan, Carlo, Colby, Donn J, Chomchey, Nitiya, Prueksakaew, Peeriya, Pinyakorn, Suteeraporn, Trichavaroj, Rapee, Vasan, Sandhya, Manasnayakorn, Sopark, Reilly, Cavan, Helgeson, Erika, Anderson, Jodi, David, Caitlin, Zulk, Jacob, de Souza, Mark, Tovanabutra, Sodsai, Schuetz, Alexandra, Robb, Merlin L, Douek, Daniel C, Phanuphak, Nittaya, Haase, Ashley, Ananworanich, Jintanat, Schacker, Timothy W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9200151/
https://www.ncbi.nlm.nih.gov/pubmed/35275599
http://dx.doi.org/10.1093/infdis/jiac089
Descripción
Sumario:Starting antiretroviral therapy (ART) in Fiebig 1 acute HIV infection limits the size of viral reservoirs in lymphoid tissues, but does not impact time to virus rebound during a treatment interruption. To better understand why the reduced reservoir size did not increase the time to rebound we measured the frequency and location of HIV RNA(+) cells in lymph nodes from participants in the RV254 acute infection cohort. HIV RNA(+) cells were detected more frequently and in greater numbers when ART was initiated in Fiebig 1 compared to later Fiebig stages and were localized to the T-cell zone compared to the B-cell follicle with treatment in later Fiebig stages. Variability of virus production in people treated during acute infection suggests that the balance between virus-producing cells and the immune response to clear infected cells rapidly evolves during the earliest stages of infection. Clinical Trials Registration: NCT02919306.